SUPPLEMENT
Q1 2025 — Other Financial Disclosures
Q1 2025PDF · 14 pages297 KB
Table 1: Sales by Segment 1 Table 2: Sales by Geographic Area 2 Table 3: Sales of Key Products/Franchises 3 - 7 Table 3a: Supplemental Sales Reconciliation 8 Table 4: Condensed Consolidated Statement of Earnings - QTD 9 Table 5: Non-GAAP Adjusted Operational Sales Growth - QTD 10 Table 6: Non-GAAP Adjusted Net Earnings 11 Table 7: Non-GAAP P&L by Segment Reconciliation 2025 12 Table 8: Non-GAAP P&L by Segment Reconciliation 2024 13 First Quarter 2025 Other Financial Disclosures Table of Contents -- 1 of 14 -- Johnson & Johnson and Subsidiaries Supplementary Sales Data (Unaudited; Dollars in Millions) 2025 2024 Total Operations Currency Sales to customers by segment of business Innovative Medicine U.S. 8,092 $ 7,612 6.3 % 6.3 - International 5,781 5,950 (2.9) 1.5 (4.4) 13,873 13,562 2.3 4.2 (1.9) MedTech U.S. 4,213 4,008 5.1 5.1 - International 3,807 3,813 (0.2) 3.0 (3.2) 8,020 7,821 2.5 4.1 (1.6) U.S. 12,305 11,620 5.9 5.9 - International 9,588 9,763 (1.8) 2.1 (3.9) Worldwide 21,893 $ 21,383 2.4 % 4.2 (1.8) Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. FIRST QUARTER Percent Change -- 2 of 14 -- Johnson & Johnson and Subsidiaries Supplementary Sales Data (Unaudited; Dollars in Millions) 2025 2024 Total Operations Currency Sales to customers by geographic area U.S. 12,305 $ 11,620 5.9 % 5.9 - Europe 5,110 5,163 (1.0) 2.2 (3.2) Western Hemisphere excluding U.S. 1,167 1,194 (2.3) 9.2 (11.5) Asia-Pacific, Africa 3,311 3,406 (2.8) (0.6) (2.2) International 9,588 9,763 (1.8) 2.1 (3.9) Worldwide 21,893 $ 21,383 2.4 % 4.2 (1.8) Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. FIRST QUARTER Percent Change -- 3 of 14 -- REPORTED SALES vs. PRIOR PERIOD ($MM) FIRST QUARTER INNOVATIVE MEDICINE SEGMENT (2) 2025 2024 Reported Operational (1) Currency ONCOLOGY US 3,013 $ 2,383 26.4% 26.4% - Intl 2,664 2,430 9.6% 14.4% -4.8% WW 5,678 4,814 17.9% 20.4% -2.5% CARVYKTI US 318 140 * * - Intl 51 16 * * * WW 369 157 * * * DARZALEX US 1,829 1,464 24.9% 24.9% - Intl 1,409 1,228 14.7% 19.8% -5.1% WW 3,237 2,692 20.3% 22.5% -2.2% ERLEADA US 292 285 2.5% 2.5% - Intl 479 404 18.5% 23.1% -4.6% WW 771 689 11.9% 14.6% -2.7% IMBRUVICA US 235 265 -11.5% -11.5% - Intl 474 518 -8.5% -4.2% -4.3% WW 709 784 -9.5% -6.7% -2.8% RYBREVANT / LAZCLUZE (3) US 113 36 * * - Intl 28 11 * * * WW 141 47 * * * TALVEY (3) US 68 50 35.2% 35.2% - Intl 18 8 * * * WW 86 58 48.4% 50.2% -1.8% TECVAYLI US 105 101 4.9% 4.9% - Intl 46 33 38.8% 45.9% -7.1% WW 151 133 13.3% 15.0% -1.7% ZYTIGA / abiraterone acetate US 7 9 -24.3% -24.3% - Intl 118 172 -31.3% -28.5% -2.8% WW 125 181 -30.9% -28.3% -2.6% OTHER ONCOLOGY (3) US 47 33 42.9% 42.9% - Intl 42 41 4.6% 10.1% -5.5% WW 89 73 21.7% 24.7% -3.0% See footnotes at end of schedule % Change -- 4 of 14 -- REPORTED SALES vs. PRIOR PERIOD ($MM) FIRST QUARTER 2025 2024 Reported Operational (1) Currency IMMUNOLOGY US 2,196 2,453 -10.5% -10.5% - Intl 1,510 1,794 -15.8% -11.5% -4.3% WW 3,707 4,247 -12.7% -10.9% -1.8% REMICADE US 314 266 18.1% 18.1% - US Exports (4) 10 27 -64.2% -64.2% - Intl 143 141 1.3% 6.8% -5.5% WW 467 434 7.5% 9.3% -1.8% SIMPONI / SIMPONI ARIA US 292 254 14.8% 14.8% - Intl 366 299 22.4% 29.7% -7.3% WW 659 554 18.9% 22.9% -4.0% STELARA US 981 1,396 -29.8% -29.8% - Intl 644 1,055 -38.9% -35.8% -3.1% WW 1,625 2,451 -33.7% -32.3% -1.4% TREMFYA US 599 509 17.6% 17.6% - Intl 356 299 19.2% 24.4% -5.2% WW 956 808 18.2% 20.1% -1.9% OTHER IMMUNOLOGY US 1 0 * * - Intl 0 0 - - - WW 1 0 * * - NEUROSCIENCE US 968 1,054 -8.1% -8.1% - Intl 679 749 -9.3% -5.5% -3.8% WW 1,647 1,803 -8.6% -7.0% -1.6% CONCERTA / Methylphenidate US 38 41 -7.4% -7.4% - Intl 110 136 -18.9% -15.2% -3.7% WW 148 177 -16.3% -13.4% -2.9% INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA US 625 765 -18.2% -18.2% - Intl 277 292 -4.9% -1.1% -3.8% WW 903 1,056 -14.5% -13.5% -1.0% SPRAVATO US 276 191 45.0% 45.0% - Intl 43 34 25.0% 31.7% -6.7% WW 320 225 41.9% 42.9% -1.0% OTHER NEUROSCIENCE US 28 58 -50.6% -50.6% - Intl 248 287 -13.4% -9.8% -3.6% WW 277 345 -19.6% -16.7% -2.9% See footnotes at end of schedule % Change -- 5 of 14 -- REPORTED SALES vs. PRIOR PERIOD ($MM) FIRST QUARTER 2025 2024 Reported Operational (1) Currency PULMONARY HYPERTENSION US 744 766 -2.9% -2.9% - Intl 281 283 -0.6% 3.2% -3.8% WW 1,025 1,049 -2.3% -1.2% -1.1% OPSUMIT / OPSYNVI (3) US 363 356 2.1% 2.1% - Intl 159 169 -6.0% -2.5% -3.5% WW 522 524 -0.5% 0.6% -1.1% UPTRAVI US 365 392 -6.9% -6.9% - Intl 86 76 13.4% 17.5% -4.1% WW 451 468 -3.6% -2.9% -0.7% OTHER PULMONARY HYPERTENSION(3) US 15 18 -12.7% -12.7% - Intl 37 39 -4.6% -0.3% -4.3% WW 52 56 -7.2% -4.3% -2.9% INFECTIOUS DISEASES US 315 324 -2.8% -2.8% - Intl 487 497 -1.9% 1.9% -3.8% WW 802 821 -2.2% 0.1% -2.3% EDURANT / rilpivirine US 8 8 -1.3% -1.3% - Intl 350 315 11.0% 14.7% -3.7% WW 358 323 10.7% 14.3% -3.6% PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA US 305 314 -2.9% -2.9% - Intl 98 104 -6.2% -0.6% -5.6% WW 403 418 -3.7% -2.3% -1.4% OTHER INFECTIOUS DISEASES (3) US 2 2 7.7% 7.7% - Intl 39 77 -48.8% -47.0% -1.8% WW 41 78 -47.6% -45.9% -1.7% CARDIOVASCULAR / METABOLISM / OTHER US 855 631 35.4% 35.4% - Intl 158 197 -19.7% -15.3% -4.4% WW 1,013 829 22.3% 23.4% -1.1% XARELTO US 690 518 33.3% 33.3% - Intl - - - - - WW 690 518 33.3% 33.3% - OTHER US 165 114 45.0% 45.0% - Intl 158 197 -19.7% -15.3% -4.4% WW 323 311 3.9% 6.7% -2.8% TOTAL INNOVATIVE MEDICINE US 8,092 7,612 6.3% 6.3% - Intl 5,781 5,950 -2.9% 1.5% -4.4% WW 13,873 $ 13,562 2.3% 4.2% -1.9% See footnotes at end of schedule % Change -- 6 of 14 -- REPORTED SALES vs. PRIOR PERIOD ($MM) FIRST QUARTER MEDTECH SEGMENT (2) 2025 2024 Reported Operational (1) Currency CARDIOVASCULAR US 1,261 $ 1,025 23.0% 23.0% - Intl 842 781 7.8% 10.7% -2.9% WW 2,103 1,806 16.4% 17.7% -1.3% ELECTROPHYSIOLOGY US 684 692 -1.1% -1.1% - Intl 638 652 -2.0% 0.7% -2.7% WW 1,323 1,344 -1.6% -0.2% -1.4% ABIOMED US 339 303 11.9% 11.9% - Intl 81 67 19.7% 23.6% -3.9% WW 420 371 13.3% 14.0% -0.7% SHOCKWAVE (5) US 206 - * * - Intl 52 - * * - WW 258 - * * - OTHER CARDIOVASCULAR US 32 30 7.1% 7.1% - Intl 72 62 15.1% 17.4% -2.3% WW 103 92 12.5% 14.1% -1.6% ORTHOPAEDICS US 1,384 1,448 -4.4% -4.4% - Intl 857 892 -3.9% -0.9% -3.0% WW 2,241 2,340 -4.2% -3.1% -1.1% HIPS US 263 270 -2.5% -2.5% - Intl 146 152 -4.0% -0.8% -3.2% WW 409 422 -3.1% -1.9% -1.2% KNEES US 231 242 -4.3% -4.3% - Intl 158 160 -1.0% 2.1% -3.1% WW 389 401 -3.0% -1.7% -1.3% TRAUMA US 502 504 -0.5% -0.5% - Intl 270 261 3.7% 7.2% -3.5% WW 772 765 0.9% 2.1% -1.2% SPINE, SPORTS & OTHER US 388 432 -10.2% -10.2% - Intl 283 320 -11.6% -8.9% -2.7% WW 671 752 -10.8% -9.7% -1.1% See footnotes at end of schedule % Change -- 7 of 14 -- REPORTED SALES vs. PRIOR PERIOD ($MM) FIRST QUARTER 2025 2024 Reported Operational (1) Currency SURGERY US 1,002 987 1.5% 1.5% - Intl 1,394 1,429 -2.5% 0.8% -3.3% WW 2,396 2,416 -0.8% 1.1% -1.9% ADVANCED US 457 446 2.7% 2.7% - Intl 616 641 -4.0% -1.0% -3.0% WW 1,073 1,087 -1.2% 0.5% -1.7% GENERAL US 544 542 0.5% 0.5% - Intl 778 788 -1.2% 2.3% -3.5% WW 1,323 1,330 -0.5% 1.6% -2.1% VISION US 566 547 3.4% 3.4% - Intl 713 710 0.4% 3.9% -3.5% WW 1,279 1,258 1.7% 3.7% -2.0% CONTACT LENSES / OTHER US 452 438 3.1% 3.1% - Intl 467 472 -1.1% 2.4% -3.5% WW 919 910 1.0% 2.7% -1.7% SURGICAL US 114 110 4.3% 4.3% - Intl 246 238 3.4% 7.1% -3.7% WW 361 348 3.7% 6.2% -2.5% TOTAL MEDTECH US 4,213 4,008 5.1% 5.1% - Intl 3,807 3,813 -0.2% 3.0% -3.2% WW 8,020 $ 7,821 2.5% 4.1% -1.6% * Percentage greater than 100% or not meaningful (1) Operational growth excludes the effect of translational currency (2) Unaudited (3) See Supplemental Sales Information Schedule (4) Reported as U.S. sales (5) Acquired on May 31, 2024 Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely % Change -- 8 of 14 -- 2023 2024 Full Year Q1 Q2 Q3 Q4 Full Year INNOVATIVE MEDICINE SEGMENT ONCOLOGY RYBREVANT / LAZCLUZE US 66 36 52 68 101 257 INTL 27 11 17 21 21 70 WW 93 47 69 89 122 327 TALVEY US 56 50 59 64 68 241 INTL 7 8 9 12 17 46 WW 63 58 69 75 85 287 OTHER ONCOLOGY US 93 33 37 36 39 145 INTL 235 41 45 50 36 172 WW 328 73 83 86 75 317 PULMONARY HYPERTENSION OPSUMIT / OPSYNVI US 1,292 356 376 417 408 1,557 INTL 681 169 171 166 162 668 WW 1,973 524 548 583 570 2,225 OTHER PULMONARY HYPERTENSION US 79 18 17 21 19 75 INTL 182 39 49 39 38 165 WW 260 56 67 60 57 240 INFECTIOUS DISEASES OTHER INFECTIOUS DISEASES (1) US 19 2 5 3 1 11 INTL 1,395 77 227 54 43 401 WW 1,414 78 233 56 45 412 (1) Other Infectious Diseases is inclusive of COVID-19 Vaccine sales, which were previously disclosed separately Note: Columns and rows within tables may not add due to rounding 2024 Supplemental Sales Information (Unaudited) (Dollars in Millions) -- 9 of 14 -- Johnson & Johnson and Subsidiaries Condensed Consolidated Statement of Earnings (Unaudited; in Millions Except Per Share Figures) Percent Percent Percent Increase Amount to Sales Amount to Sales (Decrease) Sales to customers 21,893 $ 100.0 21,383 $ 100.0 2.4 Cost of products sold 7,357 33.6 6,511 30.4 13.0 Gross Profit 14,536 66.4 14,872 69.6 (2.3) Selling, marketing and administrative expenses 5,112 23.3 5,257 24.6 (2.8) Research and development expense 3,225 14.7 3,542 16.6 (8.9) Interest (income) expense, net (128) (0.6) (209) (1.0) Other (income) expense, net (7,321) (33.4) 2,404 11.2 Restructuring 17 0.1 164 0.8 Earnings before provision for taxes on income 13,631 62.3 3,714 17.4 267.0 Provision for taxes on income 2,632 12.1 459 2.2 473.4 Net earnings 10,999 $ 50.2 3,255 $ 15.2 237.9 Net earnings per share (Diluted) 4.54 $ 1.34 $ 238.8 Average shares outstanding (Diluted) 2,423.8 2,430.1 Effective tax rate 19.3 % 12.4 % Adjusted earnings before provision for taxes and net earnings (1) Earnings before provision for taxes on income 8,011 $ 36.6 7,877 $ 36.8 1.7 Net earnings 6,706 $ 30.6 6,580 $ 30.8 1.9 Net earnings per share (Diluted) 2.77 $ 2.71 $ 2.2 Effective tax rate 16.3 % 16.5 % (1) See Reconciliation of Non-GAAP Financial Measures. FIRST QUARTER 2025 2024 -- 10 of 14 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measure Innovative Medicine MedTech Total WW As Reported 2.3% 2.5% 2.4% U.S. 6.3% 5.1% 5.9% International (2.9)% (0.2)% (1.8)% WW Currency (1.9) (1.6) (1.8) U.S. - - - International (4.4) (3.2) (3.9) WW Operational 4.2% 4.1% 4.2% U.S. 6.3% 5.1% 5.9% International 1.5% 3.0% 2.1% Shockwave (3.3) (1.2) U.S. (5.1) (1.8) International (1.4) (0.5) All Other Acquisitions and Divestitures (A&D) 0.2 0.5 0.3 U.S. 0.0 0.9 0.3 International 0.4 0.2 0.3 WW Adjusted Operational Ex A&D 4.4% 1.3% 3.3% U.S. 6.3% 0.9% 4.4% International 1.9% 1.8% 1.9% Adjusted Operational Sales Growth FIRST QUARTER 2025 ACTUAL vs. 2024 ACTUAL Segments Note: Percentages are based on actual, non-rounded figures and may not sum -- 11 of 14 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures (Dollars in Millions Except Per Share Data) 2025 2024 Net Earnings, after tax- as reported $10,999 $3,255 Pre-tax Adjustments Litigation related (6,966) 2,726 Intangible Asset Amortization expense 1,120 1,078 Restructuring related 1 55 171 Acquisition, integration and divestiture related 132 148 (Gains)/losses on securities 39 (20) Medical Device Regulation - 51 COVID-19 Vaccine related costs - 9 Tax Adjustments Tax impact on special item adjustments 2 1,315 (856) Tax legislation and other tax related 12 18 Adjusted Net Earnings, after tax $6,706 $6,580 Average shares outstanding (Diluted) 2,423.8 2,430.1 Adjusted net earnings per share (Diluted) $2.77 $2.71 Operational adjusted net earnings per share (Diluted) $2.81 Notes: 1 2 The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings. First Quarter In fiscal 2023, the company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within therapeutic areas. The R&D program exits are primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development. The restructuring expenses of $144 million in the fiscal first quarter of 2024 include the termination of partnered and non-partnered program costs and asset impairments. This program was completed in Q4 2024. In fiscal 2023, the company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The restructuring expenses of $55 million in the fiscal first quarter of 2025 and $27 million in the fiscal first quarter of 2024 primarily includes costs related to market and product exits. -- 12 of 14 -- Innovative Medicine First Quarter March 30, 2025 GAAP Intangible asset amortization Litigation related Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Tax legislation and other tax related First Quarter March 30, 2025 Non-GAAP Cost of products sold 4,020 $ (649) 3,371 Selling, marketing and admin expenses 2,261 2,261 Research and development expense 2,548 2,548 Other segment items (166) - - - (20) (18) - (204) Adjusted Income Before Tax by Segment 5,210 649 - - 20 18 - 5,897 MedTech First Quarter March 30, 2025 GAAP Intangible asset amortization Litigation related Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Tax legislation and other tax related First Quarter March 30, 2025 Non-GAAP Cost of products sold 3,326 $ (471) (8) (52) 2,795 Selling, marketing and admin expenses 2,656 2,656 Research and development expense 677 (6) 671 Other segment items (60) - - (47) (54) (21) - (182) Adjusted Income Before Tax by Segment 1,421 471 - 55 112 21 - 2,080 Expenses not allocated to segments First Quarter March 30, 2025 GAAP Intangible asset amortization Litigation related Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Tax legislation and other tax related First Quarter March 30, 2025 Non-GAAP Cost of products sold 11 $ 11 Selling, marketing and admin expenses 195 195 Research and development expense - Other segment items (7,206) - 6,966 - - - - (240) Adjusted Income Before Tax by Segment 7,000 - (6,966) - - - - 34 Johnson & Johnson Consolidated First Quarter March 30, 2025 GAAP Intangible asset amortization Litigation related Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Tax legislation and other tax related First Quarter March 30, 2025 Non-GAAP Cost of products sold 7,357 $ (1,120) (8) (52) - 6,177 Selling, marketing and admin expenses 5,112 5,112 Research and development expense 3,225 (6) 3,219 Other (Income) / Expense (7,321) - 6,966 (30) (74) (39) (498) In-process research and development impairments - - Interest (Income)/Expense (128) (128) Restructuring 17 (17) - Adjusted Income Before Tax 13,631 1,120 (6,966) 55 132 39 - 8,011 Provision for taxes on income 2,632 188 (1,553) 11 30 9 (12) 1,305 Net Earnings 10,999 932 (5,413) 44 102 30 12 6,706 Johnson & Johnson and Subsidiaries GAAP to Non-GAAP Reconciliation $ in Millions Year to Date -- 13 of 14 -- Innovative Medicine First Quarter March 31, 2024 GAAP Intangible asset amortization Litigation related Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Medical Device Regulation COVID-19 Vaccine Related Costs Tax legislation and other tax related First Quarter March 31, 2024 Non-GAAP Cost of products sold 3,370 $ (698) (2) 2,670 Selling, marketing and admin expenses 2,438 2,438 Research and development expense 2,896 (7) 2,889 Other segment items (111) (144) (47) 55 (247) Adjusted Income Before Tax by Segment 4,969 698 - 144 47 (55) - 9 - 5,812 MedTech First Quarter March 31, 2024 GAAP Intangible asset amortization Litigation related Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Medical Device Regulation COVID-19 Vaccine Related Costs Tax legislation and other tax related First Quarter March 31, 2024 Non-GAAP Cost of products sold 3,120 $ (380) (7) (20) 2,713 Selling, marketing and admin expenses 2,582 (4) 2,578 Research and development expense 646 (18) (27) 601 Other segment items (47) (20) (43) (22) (132) Adjusted Income Before Tax by Segment 1,520 380 - 27 61 22 51 - - 2,061 Expenses not allocated to segments First Quarter March 31, 2024 GAAP Intangible asset amortization Litigation related Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Medical Device Regulation COVID-19 Vaccine Related Costs Tax legislation and other tax related First Quarter March 31, 2024 Non-GAAP Cost of products sold 21 $ 21 Selling, marketing and admin expenses 237 237 Research and development expense - - Other segment items 2,517 (2,726) (40) (13) (262) Adjusted Income Before Tax by Segment (2,775) - 2,726 - 40 13 - - - 4 Johnson & Johnson Consolidated First Quarter March 31, 2024 GAAP Intangible asset amortization Litigation related Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Medical Device Regulation COVID-19 Vaccine Related Costs Tax legislation and other tax related First Quarter March 31, 2024 Non-GAAP Cost of products sold 6,511 $ (1,078) (7) (20) (2) 5,404 Selling, marketing and admin expenses 5,257 (4) 5,253 Research and development expense 3,542 (18) (27) (7) 3,490 Other (Income) / Expense 2,404 (2,726) (130) 20 (432) In-process research and development impairments - - Interest (Income)/Expense (209) (209) Restructuring 164 (164) - Adjusted Income Before Tax 3,714 1,078 2,726 171 148 (20) 51 9 - 7,877 Provision for taxes on income 459 148 627 39 38 (7) 9 2 (18) 1,297 Net Earnings 3,255 930 2,099 132 110 (13) 42 7 18 6,580 Johnson & Johnson and Subsidiaries GAAP to Non-GAAP Reconciliation $ in Millions Year to Date -- 14 of 14 --